HC Wainwright Reaffirms Buy Rating for Armata Pharmaceuticals (NYSEAMERICAN:ARMP)

Armata Pharmaceuticals (NYSEAMERICAN:ARMP)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $7.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 148.23% from the stock’s previous close.

Armata Pharmaceuticals Stock Down 1.4 %

NYSEAMERICAN:ARMP traded down $0.04 during midday trading on Wednesday, hitting $2.82. The stock had a trading volume of 1,482 shares, compared to its average volume of 16,758. The stock has a market cap of $101.94 million, a P/E ratio of -1.42 and a beta of 0.96. Armata Pharmaceuticals has a one year low of $1.07 and a one year high of $5.26.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last posted its quarterly earnings results on Thursday, March 21st. The company reported ($0.55) earnings per share (EPS) for the quarter. The firm had revenue of $1.53 million for the quarter, compared to the consensus estimate of $0.68 million. Armata Pharmaceuticals had a negative return on equity of 280.95% and a negative net margin of 1,524.51%. On average, sell-side analysts anticipate that Armata Pharmaceuticals will post -1.34 EPS for the current fiscal year.

Hedge Funds Weigh In On Armata Pharmaceuticals

A hedge fund recently raised its stake in Armata Pharmaceuticals stock. SeaCrest Wealth Management LLC lifted its position in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) by 80.8% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 32,777 shares of the company’s stock after buying an additional 14,647 shares during the period. SeaCrest Wealth Management LLC owned approximately 0.09% of Armata Pharmaceuticals worth $137,000 as of its most recent SEC filing. Institutional investors and hedge funds own 3.57% of the company’s stock.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.